Contents

Current Pharmaceutical Design, Volume 20 - Number 42

Editorial

Editorial (Thematic Issue: Combined Cancer Therapy)

, 20(42): 6511 - 6512

Jasminka Pavelic


DOI: 10.2174/1381612820666140826154834




Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer

, 20(42): 6513 - 6521

Cristina Fillat, Maria Victoria Maliandi, Ana Mato-Berciano and Ramon Alemany


DOI: 10.2174/1381612820666140826152420




Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines

, 20(42): 6522 - 6528

Anne Schaap-Nutt, Dane A. Thyssen, David W. Drell and Frank Entschladen


DOI: 10.2174/1381612820666140826152610




Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer

, 20(42): 6529 - 6542

Lidija Milkovic, Werner Siems, Renate Siems and Neven Zarkovic


DOI: 10.2174/1381612820666140826152822




Attacking c-Myc: Targeted and Combined Therapies for Cancer

, 20(42): 6543 - 6554

Huilin Huang, Hengyou Weng, Hui Zhou and Lianghu Qu


DOI: 10.2174/1381612820666140826153203




The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy

, 20(42): 6555 - 6564

Tanja Matijevic Glavan and Jasminka Pavelic


DOI: 10.2174/1381612820666140826153347




NCRNA Combined Therapy as Future Treatment Option for Cancer

, 20(42): 6565 - 6574

Cornelia Braicu, Cristina Catana, George A. Calin and Ioana Berindan-Neagoe


DOI: 10.2174/1381612820666140826153529




Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance

, 20(42): 6575 - 6583

Susan B. Kesmodel, Gauri J. Sabnis, Saranya Chumsri and Angela M.H. Brodie


DOI: 10.2174/1381612820666140826153711




Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

, 20(42): 6584 - 6643

Roger Gilabert-Oriol, Alexander Weng, Benedicta von Mallinckrodt, Matthias F. Melzig, Hendrik Fuchs and Mayank Thakur


DOI: 10.2174/1381612820666140826153913




A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities

, 20(42): 6644 - 6651

Pablo Reguera, Ainhoa Madariaga and Enrique Grande


DOI: 10.2174/1381612820666140826154033




Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors

, 20(42): 6652 - 6659

Zlatko Dembic


DOI: 10.2174/1381612820666140826154147




Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease

, 20(42): 6660 - 6669

Davide Melisi, Lorenzo Calvetti, Melissa Frizziero and Giampaolo Tortora


DOI: 10.2174/1381612820666140826154327




Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments

, 20(42): 6670 - 6681

Qingshan Yang, Lisa S. Chen and Varsha Gandhi


DOI: 10.2174/1381612820666140826154451




Curcumin in Combined Cancer Therapy

, 20(42): 6682 - 6696

Koraljka Gall Troselj and Renata Novak Kujundzic


DOI: 10.2174/1381612820666140826154601




Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue

, 20(42): 6697 - 6701

Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu


DOI: 10.2174/1381612820666140826154724




Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion

, 20(42): 6702 - 6713

M. Iovino, E. Guastamacchia, V.A. Giagulli, B. Licchelli, E. Iovino and V. Triggiani


DOI: 10.2174/1381612820666140905150730




The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs

, 20(42): 6714 - 6722

Feng Wang, Junsheng Lin and Ruian Xu


DOI: 10.2174/1381612820666140929100735




Acknowledgement to Reviewers

, 20(42): 6723


DOI: 10.2174/138161282042141022122304




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science